# Study of HR20013 for Injection in Patients With Malignant Solid Tumors

> **NCT05465681** · PHASE1 · COMPLETED · sponsor: **Fujian Shengdi Pharmaceutical Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy

## Interventions

- **DRUG:** HR20013 for injection；dexamethason

## Key facts

- **NCT ID:** NCT05465681
- **Lead sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-30
- **Primary completion:** 2023-01-13
- **Final completion:** 2023-01-13
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05465681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05465681, "Study of HR20013 for Injection in Patients With Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05465681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*